Tender detail
Medicines for congenital bleeding disorders (efanesoctocog alfa and emicizumab)
Summary
Hungary’s National Health Insurance Fund is procuring medicines for congenital bleeding disorders under a two-lot framework agreement. Lot 1 covers 7,500,000 IU of efanesoctocog alfa (Altuvoct), with a required additional product rebate of 1,500,000 IU; Lot 2 covers 450,000 mg of emicizumab (Hemlibra), with a required additional product rebate of 90,000 mg. Deliveries will be made to designated user centres through 31 December 2028; the agreement may be extended once for up to 12 months.
More tender information after sign-in
The public view shows key tender details. Sign in to open official links, documents and AI tender support.